01—Abstract
Summary
Summary of the 10-K filed February 2, 2017. Cited figures are marked; the original filing is the authoritative source.
Mettler-Toledo International Inc. reported net sales of $2.51 billiona for 2016, up 5% in U.S. dollars and 7% in local currencies from $2.40 billion in 2015.
Gross profit as a percentage of net sales rose to 57.2% from 56.4%, and net earnings increased to $384.4 millionb from $352.8 million, with diluted earnings per share of $14.22 versus $12.48. Growth was broad-based, led by laboratory-related products (about 49% of 2016 net sales), with pipettes and automated chemistry cited as especially strong. Cash provided by operating activities was $443.1 million, and the company returned $500 million through share repurchases in 2016, leaving $983.4 million remaining under the program.
Balance sheet leverage increased during the year. Long-term debt rose to $875.1 millionc from $575.1 million, and total debt was $894.0 million at year end, driven largely by borrowings under the $800 million Credit Agreement, which had $395.2 million outstanding. Shareholders' equity fell to $434.9 million from $580.5 million, reflecting repurchases and $88.3 million of other comprehensive loss.
The company acquired Henry Troemner LLC for an aggregate purchase price of $95.8 milliond in the third quarter of 2016. Management remains cautious about the sales outlook given global market uncertainty, and the filing highlights significant exposure to China (15% of 2016 sales to external customers) and to Swiss franc and euro currency movements.
The company has historically not paid dividends on its common stock, and management will evaluate that policy periodically. Its risk factors emphasize international and currency exposure, competition from emerging-market rivals, system and cyber risks tied to an ongoing ERP rollout, and goodwill and intangible assets totaling $476.4 million and $167.1 million, respectively.
02—Key points
Key Highlights
- Net sales of $2,508.3 million in 2016, up 5% in U.S. dollars and 7% in local currencies, with the Troemner acquisition contributing approximately 1%
- Net earnings of $384.4 million (diluted EPS $14.22) versus $352.8 million (diluted EPS $12.48) in 2015
- Gross profit as a percentage of net sales of 57.2% in 2016, compared with 56.4% in 2015
- Laboratory-related products represented approximately 49% of 2016 net sales, growing 6% in U.S. dollars and 8% in local currencies
- Cash provided by operating activities of $443.1 million; capital expenditures of $124.0 million, including a $37 million purchase of a previously leased pipette facility
- Share repurchases of $500 million in 2016, with $983.4 million remaining under the program; no dividends have been paid historically
- Long-term debt increased to $875.1 million from $575.1 million, with $395.2 million outstanding under the $800 million Credit Agreement
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2016filed February 2, 2017Financial Statements
FY2016 against FY2015
| Line item | FY2016FY2015 | Change |
|---|---|---|
| Revenue | $2.51B$2.40B | +4.7% |
| Cost of Revenue | $767.75M$744.87M | +3.1% |
| Gross Profit | $1.44B$1.35B | +6.3% |
| R&D Expenses | $119.20M$119.08M | +0.1% |
| SG&A Expenses | $745.36M$700.81M | +6.4% |
| Interest Expense | $28.03M$27.45M | +2.1% |
| Net Income | $384.37M$352.82M | +8.9% |
| EPS (Basic) | $14.49$12.75 | +13.6% |
| EPS (Diluted) | $14.22$12.48 | +13.9% |
| Shares Outstanding (Basic) | 26.52M27.68M | −4.2% |
| Shares Outstanding (Diluted) | 27.02M28.27M | −4.4% |
05—Questions
Frequently Asked Questions
How did Mettler-Toledo's sales and profitability trend in 2016?
Net sales rose 5% in U.S. dollars to $2,508.3 million and 7% in local currencies. Gross margin improved to 57.2% from 56.4%, and net earnings increased to $384.4 million from $352.8 million. The filing attributes the gains to higher sales volume, favorable price realization and reduced material costs, partly offset by investments in the field service organization.
Which segments and regions drove results?
Laboratory-related products grew 8% in local currencies, led by pipettes and automated chemistry. Chinese Operations segment profit rose $22.4 million, and Western European Operations segment profit increased $16.1 million. Swiss Operations net sales to external customers declined 2% in U.S. dollars, reflecting soft market conditions in Switzerland.
Why did shareholders' equity decline and debt increase?
Shareholders' equity fell to $434.9 million from $580.5 million. The filing shows $500 million of share repurchases in 2016 and $88.3 million of other comprehensive loss, which included currency translation and pension-related items. Total debt rose to $894.0 million, with the increase reflecting borrowings under the Credit Agreement and the euro-denominated Senior Notes.
What are the main risks highlighted for investors?
The filing emphasizes significant exposure to China, which accounted for 15% of 2016 sales to external customers and about 30% of global production. It also highlights sensitivity to Swiss franc and euro exchange rates, a 1% strengthening of the Swiss franc against the euro reducing earnings before tax by approximately $1.5 million to $1.7 million annually, and risks tied to the ongoing global ERP implementation and cybersecurity.
06—Continue